Cargando…
Biosimilar granulocyte–colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?
Biosimilars are approved biologics with comparable quality, safety, and efficacy to a reference product. Unlike generics, which are chemically manufactured copies of small-molecule drugs with relatively simple chemical structures, the biosimilar designation is applied to drugs that are produced by l...
Autores principales: | Bonig, Halvard, Becker, Petra S, Schwebig, Arnd, Turner, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497358/ https://www.ncbi.nlm.nih.gov/pubmed/24965197 http://dx.doi.org/10.1111/trf.12770 |
Ejemplares similares
-
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Eplin, Dwight D., et al.
Publicado: (2019) -
Donor-intrinsic variables determine mobilization efficiency: analyses from a cohort of sixty twice-mobilized stem cell donors
por: Kim-Wanner, Soo-Zin, et al.
Publicado: (2020) -
Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets
por: Melve, Guro Kristin, et al.
Publicado: (2018) -
Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors
por: Hatfield, Kimberley Joanne, et al.
Publicado: (2016) -
Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)